EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
about
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceIgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachThe future of patient-derived tumor xenografts in cancer treatment.Learning from biomedical linked data to suggest valid pharmacogenes.Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide.Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Immunotherapy for lung cancer: for whom the bell tolls?Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.Thyroid Hormone, Hormone Analogs, and Angiogenesis.Tumor exosomes: cellular postmen of cancer diagnosis and personalized therapy.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers.Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma.
P2860
Q26775347-16EB47BC-B28B-4481-8FDA-7C67C464CFE2Q28655505-BA977F5C-558E-4AD1-9DE3-2687C330159AQ33361578-1EC1E84C-BC81-42D7-B72B-6C6D23CFD8F0Q33587530-C151E205-F8AF-4DF1-896F-3A5FC06E1AC4Q34347975-D04F4B4A-17A1-495A-B644-1E78346E68F5Q35663425-5CAF5A6B-E8F4-410A-B278-78E043456D2AQ35997395-2277C4BF-3D16-4EF3-8410-27D62A0D994AQ36924954-1D1C6337-59BA-494F-930D-D92C15E09DAAQ38176858-99245995-182B-476A-B0F7-BFAB0CF95A3CQ38367414-3C10262F-F5C8-4969-8A79-29281C5401BAQ38438248-DA7CDBBB-7548-49AC-8AE8-DF894BD16F90Q38564088-6909F840-C847-4EAB-980C-32BA0C85D6CDQ38693285-64EBBB22-E684-441A-A811-7E22EE2B0AC0Q38702636-87F4EDC5-B243-4358-AE70-75E211CAFBA0Q38797202-F82C45F8-85A0-46E4-BA70-BA8E6B420549Q38916518-11A10D76-25A4-4700-8C8D-7B021335D1CAQ47735795-A332F4E0-189D-4FED-BBC2-646B1727B38DQ47957249-597CEB74-2AA2-4D8A-BDEC-BDAF879FC2DFQ54340079-B9FAEF6B-DA79-4216-A299-42FFBE00B5D4Q55052075-7BDF22A0-11AA-40AE-9D61-D351A8A3F08D
P2860
EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
EGFR and KRAS mutations, and A ...... ed non-small-cell lung cancer.
@en
type
label
EGFR and KRAS mutations, and A ...... ed non-small-cell lung cancer.
@en
prefLabel
EGFR and KRAS mutations, and A ...... ed non-small-cell lung cancer.
@en
P2860
P50
P356
P1433
P1476
EGFR and KRAS mutations, and A ...... ced non-small-cell lung cancer
@en
P2093
Liliana S Carvalho
Mary O'Brien
P2860
P304
P356
10.2217/PGS.13.177
P577
2013-11-01T00:00:00Z